BellRing Brands (BRBR)
(Delayed Data from NYSE)
$57.24 USD
-0.44 (-0.76%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $57.24 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$57.24 USD
-0.44 (-0.76%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $57.24 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum A VGM
Zacks News
Here's Why You Should Invest in Align Technology (ALGN) Now
by Zacks Equity Research
Investors continue to be optimistic about Align Technology (ALGN) on robust second-quarter 2021 performance and raised guidance.
Boston Scientific's (BSX) New Buyout to Aid Clot Management
by Zacks Equity Research
The acquisition of Devoro Medical by Boston Scientific (BSX) is expected to advance the company's core emphasis on clot management.
NEOGEN (NEOG) to Enter Retail Parasiticide Space With New Buyout
by Zacks Equity Research
NEOGEN's (NEOG) acquisition of CAPInnoVet expands its Animal Safety division and offers a strategic entry into the retail parasiticide market.
Is BellRing Brands (BRBR) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Henry Schein (HSIC) Betters Strategic View With Restructure Plan
by Zacks Equity Research
Henry Schein's (HSIC) new organizational structure will continue to enhance the company's exposure to faster-growing and higher-margin markets.
Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) on strong growth in CAG business and solid global performance.
Quest Diagnostics' (DGX) COVID-19 Test Demand Up in Q3 Months
by Zacks Equity Research
The "Path Out of the Pandemic" plan of the U.S. Government, while emphasizing more on a magnified access for testing, comes as a major breakthrough for Quest Diagnostics (DGX).
Stryker's (SYK) Trauma & Extremities Arm Unveils New Product
by Zacks Equity Research
The newly launched Citrelock Tendon Fixation Device System expands Stryker's (SYK) Foot & Ankle offerings.
Align Technology (ALGN) Launches Professional Whitening System
by Zacks Equity Research
Align Technology's (ALGN) Invisalign Professional Whitening System transforms teeth whitening with an all-in-one solution, enabling Invisalign doctors to straighten and whiten teeth simultaneously.
Syneos Health's (SYNH) New Buyout Boosts Clinical Solutions Arm
by Zacks Equity Research
Syneos Health (SYNH) acquisition of StudyKIK strengthens the former's ability to provide technology and insight-driven solutions.
Medtronic's (MDT) Pilot Plan to Address SCA Care Disparities
by Zacks Equity Research
Medtronic's (MDT) pilot program offers an advanced and scalable method to use real-world clinical data which enable quicker and appropriate care for patients at-risk of SCA.
Tandem Diabetes (TNDM) Rides on Innovation Despite Cost Woes
by Zacks Equity Research
Continued adoption of Tandem Diabetes' (TNDM) t:slim X2 insulin pumps by both new and existing users is encouraging.
Here's Why You Should Invest in Charles River (CRL) Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on solid second-quarter performance and bullish 2021 guidance.
Abbott (ABT) Nutrition Sales Grow Despite Pandemic Woes
by Zacks Equity Research
Abbott's (ABT) Sales of Pedialyte, the global rehydration brand, strongly grows driven by the recently launched products and increased investments in direct consumer promotion.
Omnicell (OMCL) New Buyout Expands Patient Engagement Suite
by Zacks Equity Research
With the FDS Amplicare acquisition, Omnicell (OMCL) is expected to gain from several healthcare trends, banking on its offerings of digital technologies, SaaS solutions, and tech-enabled services.
Here's Why You Should Retain National Vision (EYE) For Now
by Zacks Equity Research
Investors are optimistic about National Vision (EYE) owing to new store growth and pandemic-induced increase in demand for the company's offerings.
Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) on solid international market performance and raised 2021 guidance.
Teleflex (TFX) Real-World Data Outcome Supports UroLift System
by Zacks Equity Research
Teleflex's (TFX) new real-world data outcomes together with product launches demonstrate the importance of UroLift System for most BPH patients.
Syneos Health (SYNH) Enhances Clinical Trials With New Pact
by Zacks Equity Research
Syneos Health (SYNH) recent partnership develops a more patient-centric travel experience, advances diversity and inclusion in clinical research.
Here's Why You Should Retain Boston Scientific (BSX) for Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) given a strong second-quarter performance and strength in the Structural Heart business.
Quest Diagnostic (DGX) Raises View on COVID-19 Testing Surge
by Zacks Equity Research
Going by the current situation of daily increase in the coronavirus case count, Quest Diagnostics (DGX) expects COVID-19 molecular testing volumes to remain stronger through the rest of the year.
ResMed (RMD)-Backed Landmark ALASKA Study Favors PAP Therapy
by Zacks Equity Research
A late-breaking abstract from ResMed (RMD) supported landmark ALASKA study reported that treatment with PAP therapy improves the likelihood of longevity in sleep apnea patients
Thermo Fisher (TMO) Introduces Vanquish Neo UHPLC System
by Zacks Equity Research
Thermo Fisher's (TMO) Nano-Capillary and Micro-Flow LC Systems will benefit principal investigators, laboratories and proteomics researchers in academia, biopharma and contract research organizations.
What Makes BellRing Brands (BRBR) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does BellRing Brands (BRBR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Medtronic's (MDT) Emprint Ablation System Study Data Positive
by Zacks Equity Research
Medtronic's (MDT) Emprint Ablation Catheter Kit received Breakthrough Device Designation status from the FDA in April 2021 and is currently in development.